Physician profile
George Rogu
NPI 1215950761
$4,931.62
in general payments reported to CMS, 2019-2025
31 companies · $1,938 in 2025
The $1,938 reported for 2025 was more than what 98% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $709 · 2020: $106 · 2021: $221 · 2022: $464 · 2023: $559 · 2024: $934 · 2025: $1,938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,167 · Acquisitions: $1,263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,167.45 |
| Acquisitions | $1,263.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,263.36 | 2025 | |
| Merck Sharp & Dohme LLC | $716.87 | 2019-2025 | Vaxneuvance, Gardasil 9, Gardasil |
| Sanofi-Aventis U.S. LLC | $692.32 | 2023-2025 | |
| Glaxosmithkline, LLC. | $489.03 | 2019-2025 | Bexsero, Penmenvy |
| Alk-Abello, INC | $206.91 | 2024-2025 | Odactra, Grastek, Ragwitek |
| Ironshore Pharmaceuticals INC. | $191.61 | 2019-2024 | |
| Pfizer INC. | $186.19 | 2019-2024 | |
| Seqirus USA INC | $153.93 | 2024-2025 | Flucelvax |
| Ars Pharmaceuticals Operations, INC. | $143.69 | 2025 | Neffy |
| Cranial Technologies, INC | $137.85 | 2020-2025 | Doc Band |
| Regeneron Healthcare Solutions, INC. | $124.99 | 2025 | |
| Sanofi Pasteur INC. | $114.66 | 2019-2025 | |
| Aytu Biopharma, INC. | $86.44 | 2020-2023 | |
| Novavax INC | $35.46 | 2024 | Novavax Covid-19 Vaccine, Adjuvanted |
| Corium, LLC | $35.36 | 2022-2024 | Azstarys |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $34.91 | 2023 | Kristalose |
| Tris Pharma INC | $30.80 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $30.61 | 2024 | Flumist Quadrivalent |
| Supernus Pharmaceuticals, INC. | $27.27 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.14 | 2021 | |
| Hologic Sales and Service, LLC | $23.55 | 2023 | Thinprep 2000 Processor |
| Vertical Pharmaceuticals, LLC | $21.94 | 2019 | |
| Qiagen, LLC | $21.03 | 2021 | |
| Novo Nordisk INC | $19.17 | 2019 | |
| Meridian Bioscience INC. | $18.98 | 2019 | |
| Medline Industries Lp | $18.18 | 2023 | |
| Kaleo, INC. | $18.06 | 2022 | |
| Sobi, INC | $17.96 | 2019 | |
| Phadia US INC. | $17.03 | 2023 | Immunocap |
| Biogen, INC. | $15.19 | 2019 | |
| Becton, Dickinson and Company | $13.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Rogu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.